Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity

Am J Physiol Regul Integr Comp Physiol. 2019 Nov 1;317(5):R662-R672. doi: 10.1152/ajpregu.00161.2019. Epub 2019 Aug 28.

Abstract

Doxorubicin (DOX) is a highly effective antitumor agent used for the treatment of a wide range of cancers. Unfortunately, DOX treatment results in cytotoxic side effects due to its accumulation within off-target tissues. DOX-induced cellular toxicity occurs as a result of increased oxidative damage, resulting in apoptosis and cell death. While there is no standard-of-care practice to prevent DOX-induced toxicity to healthy organs, exercise has been shown to prevent cellular dysfunction when combined with DOX chemotherapy. Endurance exercise stimulates numerous biochemical adaptations that promote a healthy phenotype in several vulnerable tissues without affecting the antineoplastic properties of DOX. Therefore, for the development of an effective strategy to combat the pathological effects of DOX, it is important to determine the appropriate exercise regimen to prescribe to cancer patients receiving DOX therapy and to understand the mechanisms responsible for exercise-induced protection against DOX toxicity to noncancer cells. This review summarizes the cytotoxic effects of DOX on the heart, skeletal muscle, liver, and kidneys and discusses the current understanding of the clinical benefits of regular physical activity and the potential mechanisms mediating the positive effects of exercise on each organ system.

Keywords: Adriamycin; anthracycline; antioxidants; chemotherapy; mitochondria.

Publication types

  • Review

MeSH terms

  • Adaptation, Physiological
  • Animals
  • Antibiotics, Antineoplastic / adverse effects*
  • Awards and Prizes
  • Cardiotoxicity
  • Chemical and Drug Induced Liver Injury / etiology
  • Chemical and Drug Induced Liver Injury / metabolism
  • Chemical and Drug Induced Liver Injury / physiopathology
  • Chemical and Drug Induced Liver Injury / prevention & control*
  • Cytoprotection
  • Doxorubicin / adverse effects*
  • Exercise Therapy*
  • Heart Diseases / chemically induced
  • Heart Diseases / metabolism
  • Heart Diseases / physiopathology
  • Heart Diseases / prevention & control*
  • Humans
  • Kidney Diseases / chemically induced
  • Kidney Diseases / metabolism
  • Kidney Diseases / physiopathology
  • Kidney Diseases / prevention & control*
  • Muscular Diseases / chemically induced
  • Muscular Diseases / metabolism
  • Muscular Diseases / physiopathology
  • Muscular Diseases / prevention & control*
  • Myotoxicity
  • Physical Endurance
  • Protective Factors
  • Risk Factors

Substances

  • Antibiotics, Antineoplastic
  • Doxorubicin